Actelion drops Phase III allergy drug, but miglustat approved in Japan
This article was originally published in Scrip
Executive Summary
Actelion has announced that it is discontinuing development of its orally-active CRTH2 antagonist, setipiprant, in asthma (Phase IIb) and seasonal allergic rhinitis (Phase III profiling), after "two recently concluded studies did not confirm efficacy findings made in earlier studies". On a more positive note, Actelion said that it has obtained approval for miglustat for the treatment of Niemann-Pick type C disease – an orphan neurodegenerative disease.